Snapshot from Jul 25, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Shingrix Vaccine Linked Dementia Risk
Tech medical research

Shingrix Vaccine Linked Dementia Risk

Analysis based on 8 articles · First reported Jun 15, 2026 · Last updated Jun 28, 2026

Sentiment
50
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The study's findings could significantly boost the market for the Zoster vaccine vaccine, potentially increasing sales for GSK plc as healthcare providers and older adults consider its neuroprotective benefits. This may also spur further investment in research linking vaccines to cognitive health, impacting the pharmaceutical and healthcare industries. The positive sentiment around Zoster vaccine could lead to increased stock value for GSK plc.

pharmaceuticals healthcare
Event Summary

A new study led by Kaleen Hayes of Brown University, published in Annals of Internal Medicine, found that older adults, particularly nursing home residents, who received the Zoster vaccine shingles vaccine were 24% less likely to develop dementia over a four-year period. This research, funded by GSK plc (the maker of Zoster vaccine), adds to growing evidence suggesting a link between shingles vaccination and reduced cognitive decline. While experts like Richard Dupee caution that more research is needed to definitively prove the vaccine directly prevents dementia, the findings highlight a potential dual benefit of the vaccine: preventing shingles and offering neuroprotection. The study analyzed Medicare data and health records from over 500,000 adults in skilled nursing facilities in the United States.

Key Actions
95 Zoster vaccine reduced risk
Entities Involved
oth
Zoster vaccine
Zoster vaccine is the recombinant zoster vaccine that was studied and found to be associated with a lower risk of dementia. This research highlights a potential new benefit for the vaccine, which could increase its market demand and positive perception for its maker, GSK plc.
Importance 90.0 Sentiment 60.0
stock
GSK plc
GSK plc is the maker of the Zoster vaccine vaccine. The study, although funded by GSK plc, was independently designed and conducted, and its positive findings regarding dementia risk reduction could enhance the company's reputation and vaccine sales.
Importance 80.0 Sentiment 50.0
per
Kaleen Hayes
Kaleen Hayes is the lead author of the study, an assistant professor at Brown University, whose research provides significant evidence for the link between shingles vaccination and reduced dementia risk.
Importance 70.0 Sentiment 40.0
govactor
United States — Centers for Disease Control and Prevention
The United States — Centers for Disease Control and Prevention provides recommendations for shingles vaccination and data on vaccine effectiveness, which are referenced in the articles to support the importance of the vaccine.
Importance 30.0 Sentiment 20.0
per
Richard Dupee
Richard Dupee is a primary care physician and chief of geriatrics service at Tufts Medical Center who commented on the study, emphasizing the need for more research before recommending the vaccine specifically for dementia prevention.
Importance 10.0 Sentiment 10.0
oth
Tufts Medical Center
Tufts Medical Center is the institution where Dr. Richard Dupee, a primary care physician, is affiliated. His comments provide an expert perspective on the study's implications.
Importance 10.0 Sentiment 10.0
cnt
United States
The United States is the country where the study was conducted, focusing on the Zoster vaccine vaccine available in its market and utilizing Medicare data from its nursing facilities.
Importance 5.0 Sentiment 0.0
Relationships
GSK plc related ↔ United States
United States — Centers for Disease Control and Prevention related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.